The dataset shows that vaccine developers based in high-income countries have primarily selected manufacturing partners also based in high income countries (80%, 56/70). In contrast, vaccine developers from India (Bharat Biotech), China (Sinopharm, Sinovac, and CanSino), and Russia (Gamaleya) have primarily selected manufacturing partners that are also based in middle income countries (87%, 33/38).
There is little information on the precise details of these arrangements. For example, information on projected doses is absent for 40% (43/108) of the arrangements in the dataset. Where available, total projected doses range widely from 2 million to 1 billion total doses, and from 40 million to 1 billion doses/year. In addition, it is unclear for many of these arrangements what services are being provided (e.g., fill-and-finish or bulk substance production). Most of these arrangements appear to be solely for manufacturing, but a small proportion (13%, 14/108) are reported to include licensing or distribution rights.